Literature DB >> 33515253

Tocilizumab in Coronavirus Disease 2019: Give It Time!

Quentin Richier1,2, Léo Plaçais3,4, Karine Lacombe1,4, Olivier Hermine2,3,5.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2021        PMID： 33515253      PMCID： PMC7929041          DOI： 10.1093/cid/ciab081

Source DB:  PubMed          Journal:  Clin Infect Dis        ISSN： 1058-4838            Impact factor:   9.079


× No keyword cloud information.
  2 in total

Review 1.  Tocilizumab in COVID-19 pneumonia: Practical proposals based on a narrative review of randomised trials.

Authors:  Timothée Klopfenstein; Vincent Gendrin; N'dri Juliette Kadiane-Oussou; Thierry Conrozier; Souheil Zayet
Journal:  Rev Med Virol       Date:  2021-04-21       Impact factor: 11.043

Review 2.  Systematic Review and Subgroup Meta-analysis of Randomized Trials to Determine Tocilizumab's Place in COVID-19 Pneumonia.

Authors:  Timothée Klopfenstein; Vincent Gendrin; Aurélie Gerazime; Thierry Conrozier; Jean-Charles Balblanc; Pierre-Yves Royer; Anne Lohse; Chaouki Mezher; Lynda Toko; Cerise Guillochon; Julio Badie; Alix Pierron; N 'dri Juliette Kadiane-Oussou; Marc Puyraveau; Souheil Zayet
Journal:  Infect Dis Ther       Date:  2021-07-11
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.